Evidence map›Paper›PMID 21803744›Full record

ArticleCancer research2011

Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma.

Thaddeus D Allen, Elena M Rodriguez, Kirk D Jones, J Michael Bishop

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Cell signaling inFrontiers in cellular and infection microbiology · 2025
    Review
  4. Review
  5. Journal of Cancer · 2024
    Article
  6. Article
  7. Review
  8. International journal of general medicine · 2023
    Article
  9. Article
  10. Article
  11. Notch signaling pathway: architecture, disease, and therapeutics.Signal transduction and targeted therapy · 2022
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Notch Transduction in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2020
    Review
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Thaddeus D AllenG.W. Hooper Research Foundation, University of California, San Francisco, San Francisco, California 94143-0552, USA. Thaddeus.Allen@ucsf.edu
Elena M Rodriguez
Kirk D Jones
J Michael Bishop
San Francisco Foundation · USUniversity of California, San Francisco · US

Funding

THE MOLECULAR ANALYSIS OF TUMOR VIRUSEST32CA009043 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BISHOP, J. MICHAEL · 1985 to 2009
$5.9M
NCI NIH HHS CA009043NCI NIH HHS T32 CA009043
6 · The paper itself

Abstract

Notch1 encodes the canonical member of the mammalian Notch receptor family. Activating lesions frequently affect Notch1 in T-cell acute lymphoblastic leukemia (T-ALL) and, recently, have been found in non-small-cell lung cancer (NSCLC) as well. We explored the oncogenic potential of activated Notch1 in the lung by developing a transgenic mouse model in which activated Notch1 was overexpressed in the alveolar epithelium. The initial response to activated Notch1 was proliferation and the accumulation of alveolar hyperplasia, which was then promptly cleared by apoptosis. After an extended latency period, however, pulmonary adenomas appeared in the transgenic mice but failed to progress to become carcinomas. Interestingly, Myc and MycL1 were expressed in the adenomas, suggesting that selection for enhanced Myc activity may facilitate tumorigenesis. Using mice engineered to coexpress activated Notch1 and Myc, we found that supplementing Myc expression resulted in increased frequency of Notch1 intracellular domain (N1ICD)-induced adenoma formation and enabled progression to adenocarcinoma and metastases. Cooperation stemmed from synergistic activation of tumor cell cycling, a process that apparently countered any impedance to tumorigenesis posed by Myc and/or activated Notch1-induced apoptosis. Significantly, cooperation was independent of RAS activation. Taken together, the data suggest that activated Notch1 substitutes for RAS activation synergistically with Myc in the development of NSCLC. These tumor models should be valuable for exploring the role of activated Notch1 in the genesis of NSCLC and for testing therapies targeting either activated Notch1 or its downstream effectors.

Indexed as

AdenocarcinomaAdenomaAnimalsApoptosisCell Transformation, NeoplasticGenes, mycHumansHyperplasiaLung NeoplasmsMiceMice, TransgenicProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mdm2Proto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)Pulmonary AlveoliMycl1 protein, mouseMYC protein, humanMyc protein, mouseProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mdm2Proto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)Receptor, Notch1Tumor Suppressor Protein p14ARF

Identifiers

PMID21803744
PMCPMC3174331
OpenAlexW2151601849

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.